Haemonetics Corp (HAE)
83.62
+2.38
(+2.93%)
USD |
NYSE |
Apr 22, 16:00
83.64
+0.02
(+0.02%)
Pre-Market: 20:00
Haemonetics Research and Development Expense (Quarterly): 13.26M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 13.26M |
| September 30, 2023 | 12.66M |
| June 30, 2023 | 12.65M |
| March 31, 2023 | 15.64M |
| December 31, 2022 | 12.69M |
| September 30, 2022 | 10.90M |
| June 30, 2022 | 10.90M |
| March 31, 2022 | 13.21M |
| December 31, 2021 | 10.04M |
| September 30, 2021 | 10.85M |
| June 30, 2021 | 12.70M |
| March 31, 2021 | 10.84M |
| December 31, 2020 | 7.501M |
| September 30, 2020 | 6.763M |
| June 30, 2020 | 7.75M |
| March 31, 2020 | 8.974M |
| December 31, 2019 | 7.00M |
| September 30, 2019 | 7.422M |
| June 30, 2019 | 7.487M |
| March 31, 2019 | 8.747M |
| December 31, 2018 | 8.978M |
| September 30, 2018 | 8.583M |
| June 30, 2018 | 9.406M |
| March 31, 2018 | 11.09M |
| December 31, 2017 | 12.43M |
| Date | Value |
|---|---|
| September 30, 2017 | 7.521M |
| June 30, 2017 | 8.193M |
| March 31, 2017 | 9.321M |
| December 31, 2016 | 8.462M |
| September 30, 2016 | 8.336M |
| June 30, 2016 | 11.44M |
| March 31, 2016 | 11.15M |
| December 31, 2015 | 10.94M |
| September 30, 2015 | 11.55M |
| June 30, 2015 | 11.32M |
| March 31, 2015 | 17.22M |
| December 31, 2014 | 10.64M |
| September 30, 2014 | 10.94M |
| June 30, 2014 | 15.38M |
| March 31, 2014 | 13.84M |
| December 31, 2013 | 14.21M |
| September 30, 2013 | 14.95M |
| June 30, 2013 | 11.21M |
| March 31, 2013 | 13.57M |
| December 31, 2012 | 10.59M |
| September 30, 2012 | 10.83M |
| June 30, 2012 | 9.409M |
| March 31, 2012 | 8.611M |
| December 31, 2011 | 9.232M |
| September 30, 2011 | 10.35M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
6.763M
Minimum
Sep 2020
15.64M
Maximum
Mar 2023
10.49M
Average
10.85M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| Stryker Corp | 350.00M |
| Boston Scientific Corp | 363.00M |
| Insulet Corp | 42.00M |
| ResMed Inc | 73.88M |
| Masimo Corp | 38.00M |